Registry for patients with relapsed or refractory follicular lymphoma
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
This study is collecting information from patients with follicular lymphoma who have not responded to their first treatment to help find better ways to treat them in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Hematology Association - Lymphoma Group Academic / other |
| Locations | 11 sites (Split and 10 other locations) |
| Trial ID | NCT04587388 on ClinicalTrials.gov |
What this trial studies
This registry collects data on patients with histologically confirmed follicular lymphoma who experience refractory or relapsed disease after first-line treatment. Patients are registered at the time of their first event, which is documented through biopsy, imaging, or clinical evaluation. The study aims to gather clinical and biological information to develop optimal treatment strategies for these patients. A panel of expert pathologists will review the histopathology of the cases to ensure accurate diagnosis and treatment planning.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years with a confirmed diagnosis of follicular lymphoma who have experienced refractory or relapsed disease after initial treatment.
Not a fit: Patients under 18 years old or those without a confirmed diagnosis of follicular lymphoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with refractory or relapsed follicular lymphoma.
How similar studies have performed: Other studies have shown success in utilizing registries to improve treatment outcomes for similar hematological conditions, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy; * All stages at the time of relapse; * Histological grade 1-3a at the time of initial diagnosis; * Age over 18 years; * Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested * Diagnostic material available for review; * Written informed consent. Exclusion Criteria: • Age \< 18 years
Where this trial is running
Split and 10 other locations
- Klinički Bolnički Centar Split — Split, Croatia (Recruiting)
- AOU Città della Salute e della Scienza di Torino — Torino, Italy (Recruiting)
- Academic Medical Center — Amsterdam, Netherlands (Recruiting)
- University Medical Center Groningen — Groningen, Netherlands (Recruiting)
- Instituto Português de Oncologia Francisco Gentil — Lisbon, Portugal (Recruiting)
- Hospital Clinic de Barcelona — Barcelona, Spain (Recruiting)
- Hospital 12 de Octubre — Madrid, Spain (Recruiting)
- Hospital Jose Maria Morales Meseguer — Murcia, Spain (Recruiting)
- Hospital de Son Llàtzer — Palma, Spain (Recruiting)
- Hospital Universitario de Salamanca — Salamanca, Spain (Recruiting)
- Kiev National Cancer Institute — Kiev, Ukraine (Recruiting)
Study contacts
- Study coordinator: Sanne Tonino, MD
- Email: hemat.trial@amc.nl
- Phone: 020 56 64447
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.